| Literature DB >> 35889752 |
Ángel Arturo López-González1,2,3, Bárbara Altisench Jané4, Luis Masmiquel Comas3,4,5, Sebastiana Arroyo Bote1,2, Hilda María González San Miguel1,2, José Ignacio Ramírez Manent3,4,5.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease is a chronic disease caused by the accumulation of fat in the liver related to overweight and obesity, insulin resistance, hyperglycemia, and high levels of triglycerides and leads to an increased cardiovascular risk. It is considered a global pandemic, coinciding with the pandemic in 2020 caused by the "coronavirus disease 2019" (COVID-19). Due to COVID-19, the population was placed under lockdown. The aim of our study was to evaluate how these unhealthy lifestyle modifications influenced the appearance of metabolic alterations and the increase in non-alcoholic fatty liver disease.Entities:
Keywords: COVID-19; insulin resistance; non-alcoholic fatty liver disease
Mesh:
Year: 2022 PMID: 35889752 PMCID: PMC9319232 DOI: 10.3390/nu14142795
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Characteristics of the population per year.
| N = 6236 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | ||
| Age (years) | 41.1 ± 9.9 | 42.1 ± 9.9 | 43.1 ± 9.9 | <0.001 |
| Weight (kg) | 71.7 ± 16.3 | 72.2 ± 16.4 | 73.8 ± 16.5 | <0.001 |
| BMI (kg/m2) | 25.1 ± 4.7 | 25.3 ± 4.7 | 25.9 ± 4.7 | <0.001 |
| Waist circumference (cm) | 82.8 ± 14.0 | 84.6 ± 14.1 | 87.6 ± 14.1 | <0.001 |
| Hip circumference (cm) | 98.7 ± 9.4 | 99.8 ± 9.4 | 101.5 ± 9.5 | <0.001 |
| Waist to Height ratio | 0.49 ± 0.08 | 0.50 ± 0.08 | 0.52 ± 0.08 | <0.001 |
| Waist to Hip ratio | 0.84 ± 0.10 | 0.85 ± 0.09 | 0.86 ± 0.09 | <0.001 |
| Body fat (%) | 24.5 ± 9.1 | 25.3 ± 8.7 | 26.9 ± 8.8 | <0.001 |
| SBP (mmHg) | 120.0 ± 16.8 | 121.3 ± 16.3 | 124.6 ± 16.3 | <0.001 |
| DBP (mmHg) | 76.9 ± 10.7 | 78.2 ± 10.5 | 82.8 ± 10.6 | <0.001 |
| Glycemia (mg/dL) | 90.5 ± 16.4 | 91.9 ± 15.7 | 95.4 ± 15.8 | <0.001 |
| Total cholesterol (mg/dL) | 190.7 ± 37.3 | 194.3 ± 35.3 | 202.8 ± 35.7 | <0.001 |
| HDL-c (mg/dL) | 53.9 ± 13.7 | 53.1 ± 13.4 | 50.7 ± 13.7 | <0.001 |
| LDL-c (mg/dL) | 117.4 ± 40.3 | 121.4 ± 38.5 | 131.0 ± 39.0 | <0.001 |
| Triglycerides (mg/dL) | 96.8 ± 79.2 | 98.7 ± 78.5 | 105.8 ± 78.9 | <0.001 |
| ALT (U/L) | 24.1 ± 28.5 | 25.7 ± 28.7 | 28.4 ± 28.7 | <0.001 |
| AST (U/L) | 21.7 ± 15.5 | 22.7 ± 15.6 | 24.0 ± 15.7 | <0.001 |
| GGT (U/L) | 25.8 ± 27.4 | 26.8 ± 27.4 | 28.9 ± 27.4 | <0.001 |
| N (%) | N (%) | N (%) | ||
| Women | 3236 (51.9) | 3236 (51.9) | 3236 (51.9) | |
| Men | 3000 (48.1) | 3000 (48.1) | 3000 (48.1) | |
| Smokers | 1176 (18.9) | 1202 (19.3) | 1302 (20.9) | <0.001 |
| Physical exercise | 2732 (43.8) | 2600 (41.7) | 2044 (32.8) | <0.001 |
| Social class I | 3664 (58.8) | 3664 (58.8) | 3664 (58.8) | |
| Social class II | 812 (13.0) | 812 (13.0) | 812 (13.0) | |
| Social class III | 1760 (28.2) | 1760 (28.2) | 1760 (28.2) | |
| Obesity | 846 (13.6) | 860 (13.8) | 1007 (16.1) | <0.001 |
| Diabetes type 2 | 86 (1.4) | 100 (1.6) | 140 (2.2) | <0.001 |
| Dyslipidemia | 2361 (37.9) | 2470 (39.6) | 3234 (51.9) | <0.001 |
| Metabolic Syndrome | 463 (7.4) | 865 (13.9) | 1304 (20.9) | <0.001 |
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoproteins; LDL: low-density lipoproteins; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase.
Changes in insulin resistance scales and NAFLD scales in 2018, 2019, and 2020.
| 2018 | 2019 | 2020 | Difference 2018–2019 | Difference 2019–2020 | |||
|---|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Value (%) | Value (%) | |||
| METS-IR | 35.9 ± (8.6) | 36.4 ± (8.7) | 38.1 ± 9.1 | <0.0001 | 0.49 (1.36) | 1.71 (4.71) | <0.0001 |
| TyG index | 8.1 ± 0.7 | 8.2 ± 0.7 | 8.3 ± 0.6 | <0.0001 | 0.06 (0.77) | 0.13 (1.63) | <0.0001 |
| TyG index-BMI | 204.3 ± 44.0 | 207.2 ± 43.7 | 215.3 ± 44.2 | <0.0001 | 2.88 (1.41) | 8.09 (3.9) | <0.0001 |
| TyG index-Waist circumference | 674.2 ± 137.1 | 694.3 ± 137.6 | 729.9 ± 137.6 | <0.0001 | 20.12 (2.98) | 35.57 (5.12) | <0.0001 |
| TyG index-Waist to height ratio | 4.0 ± 0.8 | 4.1 ± 0.8 | 4.3 ± 0.8 | <0.0001 | 0.12 (2.97) | 0.21 (5.4) | <0.0001 |
| Lipid accumulation product | 26.7 ± 28.5 | 27.4 ± 30.0 | 32.2 ± 32.8 | <0.0001 | 2.05 (8,30) | 5.45 (20.40) | <0.0001 |
| Fatty liver index | 25.2 ± 25.9 | 27.3 ± 26.8 | 33.0 ± 27.9 | <0.0001 | 2.09 (8.30) | 5.70 (20.89) | <0.0001 |
| Hepatic steatosis index | 34.7 ± 6.3 | 35.5 ± 6.2 | 36.7 ± 6.4 | <0.0001 | 0.84 (2.43) | 1.16 (3.27) | <0.0001 |
METS-IR: metabolic score for insulin resistance; TyG: triglyceride glucose index; BMI: body mass index.
Changes in prevalence of high values of insulin resistance scales and non-alcoholic fatty liver disease scales in non-diabetic and diabetic people in 2018, 2019, and 2020.
| Year 2018 | Year 2019 | Year 2020 | Difference 2018–2019 | Difference 2019–2020 | |||
|---|---|---|---|---|---|---|---|
| Non diabetic | n (%) | n (%) | n (%) | value (%) | value (%) | ||
| METS-IR high | 418 (6.8) | 440 (7.2) | 627 (10.3) | <0.0001 | 0.4 (5.9) | 3.1 (43.5) | <0.0001 |
| TyG index high | 1240 (20.2) | 1292 (21.1) | 1512 (24.8) | <0.0001 | 0.9 (4.5) | 3.7 (17.5) | <0.0001 |
| Lipid accumulation product high | 1376 (22.4) | 1499 (24.6) | 1974 (32.4) | <0.0001 | 2.2 (9.8) | 7.8 (31.7) | <0.0001 |
| Fatty liver index high | 796 (12.9) | 900 (14.7) | 1169 (19.2) | <0.0001 | 1.8 (14.0) | 4.5 (30.6) | <0.0001 |
| Hepatic steatosis index high | 1933 (31.4) | 1998 (32.6) | 2198 (36.1) | <0.0001 | 1.2 (3.8) | 3.5 (10.7) | <0.0001 |
| Diabetic | |||||||
| METS-IR high | 39 (45.3) | 46 (46.0) | 70 (50.0) | <0.0001 | 0.7 (1.5) | 4.0 (8.7) | <0.0001 |
| TyG index high | 41 (47.7) | 48 (48.0) | 70 (50.0) | <0.0001 | 0.3 (0.6) | 2.0 (1.2) | <0.0001 |
| Lipid accumulation product high | 36 (47.9) | 49 (49.0) | 74 (52.9) | <0.0001 | 1.1 (2.3) | 3.9 (8.0) | <0.0001 |
| Fatty liver index high | 49 (57.0) | 57 (57.0) | 82 (58.6) | <0.0001 | 0.0 (0.0) | 1.6 (2.8) | <0.0001 |
| Hepatic steatosis index high | 75 (87.2) | 90 (90.0) | 132 (94.3) | <0.0001 | 2.8 (3.2) | 4.3 (4.8) | <0.0001 |
METS-IR: metabolic score for insulin resistance; TyG: triglyceride glucose index.
Figure 1Changes in insulin resistance scales in 2018, 2019, and 2020. METS-IR: metabolic score for insulin resistance; TyG: triglyceride glucose index; BMI: body mass index; WC: waist circumference; WtHR: waist to height ratio.
Figure 2Changes in NAFLD scales in 2018, 2019, and 2020. LAP: Lipid accumulation product; FLI: fatty liver index; HIS: hepatic steatosis index.
Pearson correlation coefficients between insulin resistance scales and NAFLD scales.
| LAP | FLI | HSI | |
|---|---|---|---|
| METS-IR | 0.588 | 0.861 | 0.879 |
| TyG INDEX | 0.653 | 0.439 | 0.092 |
| TyG index BMI | 0.685 | 0.892 | 0.837 |
| TyG index waist | 0.772 | 0.910 | 0.676 |
| TyG index waist/high | 0.761 | 0.888 | 0.701 |
METS-IR: metabolic score for insulin resistance; TyG: triglyceride glucose index; BMI: body mass index; LAP: lipid accumulation product; FLI: fatty liver index; HIS: hepatic steatosis index.